Significant risk factors for intensive care unit-acquired weakness: A processing strategy based on repeated machine learning

Table 1 Analysis of factors associated with intensive care unit-acquired weakness

Parameters	ICU-AW group (n = 370)	Non-ICU-AW group (n = 693)	χ2/t/Z	P value
Sex			1.913	0.167
Male, n (%)	235 (63.51)	410 (59.16)
Female, n (%)	135 (36.49)	283 (40.84)
Age in yr, mean ± SD	65.29 ± 18.72	58.58 ± 18.75	31.013	0.000
Sepsis, n (%)	31 (8.38)	31 (4.47)	6.727	0.010
Multiple organ dysfunction syndrome, n (%)	96 (25.95)	68 (9.81)	50.307	0.000
Hypoalbuminemia, n (%)	275 (74.32)	379 (54.69)	67.286	0.000
Acute cardiogenic failure, n (%)	157 (42.43)	205 (29.58)	18.005	0.000
Respiratory failure, n (%)	231 (62.43)	277 (39.97)	83.798	0.000
Acute kidney injury, n (%)	63 (17.03)	47 (6.78)	27.956	0.000
Anemia, n (%)	191 (51.62)	229 (33.04)	35.942	0.000
Diffuse intravascular coagulation, n (%)	5 (1.35)	8 (1.15)	0.077	0.781
Stress-related gastrointestinal bleeding, n (%)	99 (26.76)	74 (10.68)	47.733	0.000
Shock, n (%)	224 (60.54)	276 (39.83)	43.152	0.000
Hypertension, n (%)	193 (52.16)	263 (37.95)	20.661	0.000
Diabetes, n (%)	83 (22.43)	133 (19.19)	1.564	0.211
Coronary atherosclerotic heart disease, n (%)	123 (33.24)	132 (19.05)	27.292	0.000
Malignant tumor, n (%)	81 (21.89)	144 (20.78)	0.179	0.673
Rehabilitation therapy, n (%)	20 (5.40)	172 (24.82)	93.687	0.000
Mechanical ventilation duration in h, M (QL, QU)	114 (9.75, 250)	0 (0, 21)	29.905	0.000
Midazolam in mg, M (QL, QU)	50 (0, 370)	0 (0,20)	127.872	0.000
Norepinephrine in mg, M (QL, QU)	20 (0, 120)	0 (0, 16)	81.127	0.000
Length of intensive care unit stay in d, M (QL, QU)	10 (6, 19)	3 (1, 4)	278.696	0.000

ICU-AW: Intensive care unit-acquired weakness.